## HEALTHY U CHIP

## PRIOR AUTHORIZATION REQUEST FORM CONSTIPATION MEDICATIONS

Amitiza<sup>®</sup>, Linzess<sup>®</sup>, Motegrity<sup>™</sup>, Movantik<sup>®</sup>, Relistor<sup>®</sup>, Symproic<sup>®</sup>, Trulance<sup>®</sup>

For authorization, please answer each question and fax this form PLUS chart notes back to the Healthy U CHIP Prior Authorization Department at 385-425-4052.

Failure to submit clinical documentation to support this request will result in a dismissal of the request.

If you have prior authorization questions, please call for assistance: 385-425-5094

Disclaimer: Prior Authorization request forms are subject to change in accordance with Federal and State notice requirements.

Date:	Member Name:	ID#:				
DOB:	Gender:	Physician:				
Office Phone:	Office Fax:	Office Contact:				

Height/Weight:

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

Preferred: □ Linzess® (linaclotide), □ lubiprostone\*, □ Movantik® (naloxegol)
Non-preferred: □ prucalopride, □ Symproic® (naldemedine), □ Trulance® (plecanatide)
Non-formulary: □ Relistor® (methylnaltrexone)

\*does not require prior authorization

Dosing/Frequency:

If the request is for reauthorization, proceed to reauthorization section						
Questions		Yes	No	Comments/Notes		
CHRONIC IDIOPATHIC CONSTIPATION						
1.	Has the member been diagnosed with Chronic Idiopathic					
	Constipation?					
2.	Has the member had a trial and failure of a laxative such as			Please provide documentation		
	lactulose or polyethylene glycol?					
3.	If the request for Linzess <sup>®</sup> , has the member had an adequate			Please provide documentation		
	trial and failure of lubiprostone?					
4.	If the request is for prucalopride or Trulance <sup>®</sup> , has the			Please provide documentation		
	member had an adequate trial and failure of Linzess <sup>®</sup> and					
	lubiprostone?					
IRRITABLE BOWEL SYNDROME WITH CONSTIPATION						
1.	Has the member been diagnosed with Irritable Bowel					
	Syndrome with constipation?					
2.	Has the member had a trial and failure of a laxative such as			Please provide documentation		
	lactulose or polyethylene glycol?					
3.	If the request is for Linzess <sup>®</sup> , has the member had an			Please provide documentation		
	adequate trial and failure of lubiprostone?					

4.	If the request is for prucalopride or Trulance <sup>®</sup> , has the member had an adequate trial and failure of Linzess <sup>®</sup> and lubiprostone?			Please provide documentation		
OPIOID INDUCED CONSTIPATION						
1.	Has the member been diagnosed with opioid induced constipation?					
2.	Has the member had a trial and failure of a laxative such as lactulose or polyethylene glycol?			Please provide documentation		
	If the request for Movantik <sup>®</sup> , has the member had an adequate trial and failure of lubiprostone?			Please provide documentation		
4.	If the request is for Symproic <sup>®</sup> , has the member had an adequate trial and failure of Movantik <sup>®</sup> and lubiprostone?			Please provide documentation		
	REAUTHORIZATIO	1	T			
1.	Is the request for reauthorization of therapy?					
2.	Has the member's therapy been re-evaluated within the past 12 months?					
3.	Has the therapy shown to be effective with an improvement in the member's condition?			Please provide documentation		
4.	Does the member show a continued medical need for the therapy?			Please provide documentation		
What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc. Additional information:						
Ph	ysician Signature:					

## \*\* Failure to submit clinical documentation to support this request will result in a dismissal of the request.\*\*

Policy: PHARM-CHIP-017 Origination Date: 07/01/2024 Reviewed/Revised Date: 04/09/2025 Next Review Date: 04/09/2026 Current Effective Date: 05/01/2025

## **Confidentiality Notice**

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.